SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood
复制标题
DOI：
10.1038/s41467-020-18468-8
复制
发表时间：
2020-09-17
影响因子：
16.6
通讯作者：
Chiu, Charles Y.
中科院分区：
文献类型：
--
作者：
Ng, Dianna L.;Goldgof, Gregory M.;Chiu, Charles Y.
鉴于迄今为止血清学检测的可用性有限，sars - cov -2特异性抗体在不同人群中的血清流行率仍不清楚。在这里，我们报告了两个旧金山湾区人群的SARS-CoV-2血清阳性率非常低。2020年4月初，387名非呼吸指征住院患者的血清反应率为0.26%，1000名献血者的血清反应率为0.1%。我们还描述了COVID-19患者免疫球蛋白g （IgG）、免疫球蛋白m （IgM）和体外中和抗体滴度的纵向动态。这3项检测的中位血清转化时间为10.3-11.0天。在症状出现后，中和抗体随着免疫球蛋白滴度的升高而升高，IgG检测和中和滴度之间的阳性率为0.93%。这些发现强调了在低流行人群中使用高度准确的检测方法进行监测研究的重要性，并提供证据表明，使用SARS-CoV-2抗核衣壳蛋白IgG和抗刺突IgM检测的血清反应性通常可预测体外中和能力。
Given the limited availability of serological testing to date, the seroprevalence of SARS-CoV-2-specific antibodies in different populations has remained unclear. Here, we report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seroreactivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications and 0.1% in 1,000 blood donors in early April 2020. We additionally describe the longitudinal dynamics of immunoglobulin-G (IgG), immunoglobulin-M (IgM), and in vitro neutralizing antibody titers in COVID-19 patients. The median time to seroconversion ranged from 10.3-11.0 days for these 3 assays. Neutralizing antibodies rose in tandem with immunoglobulin titers following symptom onset, and positive percent agreement between detection of IgG and neutralizing titers was >93%. These findings emphasize the importance of using highly accurate tests for surveillance studies in low-prevalence populations, and provide evidence that seroreactivity using SARS-CoV-2 anti-nucleocapsid protein IgG and anti-spike IgM assays are generally predictive of in vitro neutralizing capacity.